1. Home
  2. OLP vs OMER Comparison

OLP vs OMER Comparison

Compare OLP & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo One Liberty Properties Inc.

OLP

One Liberty Properties Inc.

HOLD

Current Price

$23.89

Market Cap

550.9M

Sector

Real Estate

ML Signal

HOLD

Logo Omeros Corporation

OMER

Omeros Corporation

HOLD

Current Price

$18.76

Market Cap

844.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OLP
OMER
Founded
1982
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
550.9M
844.6M
IPO Year
1995
2008

Fundamental Metrics

Financial Performance
Metric
OLP
OMER
Price
$23.89
$18.76
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
5
Target Price
$26.75
$32.50
AVG Volume (30 Days)
67.6K
2.3M
Earning Date
05-05-2026
05-14-2026
Dividend Yield
7.88%
N/A
EPS Growth
N/A
98.15
EPS
1.00
0.77
Revenue
$82,740,000.00
$29,868,000.00
Revenue This Year
$11.98
N/A
Revenue Next Year
$3.71
$233.22
P/E Ratio
$23.86
$24.35
Revenue Growth
1.02
N/A
52 Week Low
$19.62
$3.94
52 Week High
$25.88
$19.65

Technical Indicators

Market Signals
Indicator
OLP
OMER
Relative Strength Index (RSI) 43.03 70.49
Support Level $23.31 $9.12
Resistance Level $25.74 $19.65
Average True Range (ATR) 0.44 0.98
MACD -0.02 -0.05
Stochastic Oscillator 9.37 73.38

Price Performance

Historical Comparison
OLP
OMER

About OLP One Liberty Properties Inc.

One Liberty Properties Inc is a self-administered and self-managed real estate investment trust. It acquires, owns, and manages a geographically diversified portfolio consisting mainly of industrial and, to a lesser extent, retail properties, many of which are subject to long-term net leases. The trust has approximately one hundred and two properties located across several states in the United States of America. A majority of its revenue is generated in the form of rental income.

About OMER Omeros Corporation

Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.

Share on Social Networks: